MD, PhD
AP-HM
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Within the immunology laboratory of the Conception Hospital, we take care of patients suffering from immune system dysfunction: immune deficiencies, inflammatory and autoimmune diseases. In practice, we conduct specialized biology tests to quantify and qualify the immune response complexity and we contribute to the therapeutic decision-making of medical teams.
Inherently complex, these diseases are often a real challenge in terms of diagnosis, prognosis, treatment and monitoring. Our mission therefore is to accelerate the transfer of the latest science and research breakthrough to the clinic to fuel new opportunities for innovation. At the pace of discovery, the laboratory establishes normative values of new classes of immune cells and develops tests that, in turn, will increase the diagnostic power of our analysis. It also conducts interdisciplinary research programs to enhance our knowledge of immunopathology and improve the development of new experimental models.
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research. This approach requires exchanges and interdisciplinarity, two of the main attributes of Marseille Immunopole.
#cliniqueMI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Francois ROMAGNÉ
AMU, MI-mAbs
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA